SRZN

SEC source: 0000899243-21-033047 · doc4.xml · derivative · entry 7

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Common Stock · 144,667 shares

Expires not disclosed

F3 · security: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F5 · derivative.exercise_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033047 · doc4.xml · derivative · entry 6

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 144,667 shares

Expires not disclosed

F3 · security: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F5 · derivative.exercise_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033047 · doc4.xml · nonDerivative · entry 5

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,885,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1) and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033047 · doc4.xml · nonDerivative · entry 4

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1) and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033047 · doc4.xml · nonDerivative · entry 3

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1) and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033047 · doc4.xml · nonDerivative · entry 2

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,451,000

F3 · price: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033047 · doc4.xml · nonDerivative · entry 1

Consonance Life Sciences · CIK 0001824774 · Former 10% Holder

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1) and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · derivative · entry 7

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Common Stock · 144,667 shares

Expires not disclosed

F3 · security: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F5 · derivative.exercise_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · derivative · entry 6

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 144,667 shares

Expires not disclosed

F3 · security: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F5 · derivative.exercise_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · nonDerivative · entry 5

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,885,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1), and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · nonDerivative · entry 4

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1), and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · nonDerivative · entry 3

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1), and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · nonDerivative · entry 2

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,451,000

F3 · price: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033039 · doc4.xml · nonDerivative · entry 1

Soffer Benny · CIK 0001829318 · FORMER DIRECTOR

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act,

F2 · price: (Continued from footnote 1), and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · derivative · entry 7

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Common Stock · 144,667 shares

Expires not disclosed

F3 · security: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F5 · derivative.exercise_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · derivative · entry 6

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 144,667 shares

Expires not disclosed

F3 · security: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F5 · derivative.exercise_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F5 · derivative.expiration_date: Represents part of private placement units of the Issuer purchased by Consonance Life Sciences in a private placement transactions in connection with the Issuer's initial public offering for $10 per unit. Each unit consisted of one Class A Share and one-third of one private placement warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants will expire at 5:00 p.m., New York City time, five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · nonDerivative · entry 5

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,885,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934,

F2 · price: (Continued from footnote 1) as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · nonDerivative · entry 4

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934,

F2 · price: (Continued from footnote 1) as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · nonDerivative · entry 3

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934,

F2 · price: (Continued from footnote 1) as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · nonDerivative · entry 2

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,451,000

F3 · price: Pursuant to the Sponsor Letter Agreement entered into in connection with the Business Combination Agreement, Consonance Life Sciences LLC ("Consonance Life Sciences") agreed to contribute an aggregate of 759,000 Class B Ordinary Shares back to the Issuer for no additional consideration.

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-033037 · doc4.xml · nonDerivative · entry 1

Livingston Kevin Harold · CIK 0001828234 · Former Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934,

F2 · price: (Continued from footnote 1) as amended (the "Exchange Act"), pursuant to Rule 16b-3 and Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".

F4 · ownership.nature: Represents shares held by Consonance Life Sciences. Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion over the securities held by Consonance Life Sciences and may be deemed to have shared beneficial ownership of such securities. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the securities held by Consonance Life Sciences except to the extent of their pecuniary interest therein.

SEC source: 0001104659-20-131774 · a4.xml · derivative · entry 2

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131774 · a4.xml · nonDerivative · entry 1

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131773 · a4.xml · derivative · entry 2

Consonance Life Sciences · CIK 0001824774 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.direct: The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131773 · a4.xml · nonDerivative · entry 1

Consonance Life Sciences · CIK 0001824774 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,000

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.direct: The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131772 · a4.xml · derivative · entry 2

Soffer Benny · CIK 0001829318 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131772 · a4.xml · nonDerivative · entry 1

Soffer Benny · CIK 0001829318 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131769 · a4.xml · derivative · entry 2

Livingston Kevin Harold · CIK 0001828234 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-131769 · a4.xml · nonDerivative · entry 1

Livingston Kevin Harold · CIK 0001828234 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019983 · doc4a.xml · derivative · entry 2

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019983 · doc4a.xml · nonDerivative · entry 1

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019994 · doc4a.xml · derivative · entry 2

Soffer Benny · CIK 0001829318 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019994 · doc4a.xml · nonDerivative · entry 1

Soffer Benny · CIK 0001829318 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019991 · doc4a.xml · derivative · entry 2

Consonance Life Sciences · CIK 0001824774 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.direct: The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019991 · doc4a.xml · nonDerivative · entry 1

Consonance Life Sciences · CIK 0001824774 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,000

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.direct: The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019989 · doc4a.xml · derivative · entry 2

Livingston Kevin Harold · CIK 0001828234 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 144,667

Underlying: Class A Ordinary Shares · 8,000 shares

Expires not disclosed

F1 · security: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F5 · security: Includes 8,000 warrants underlying the units referred to in footnote 1.

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019989 · doc4a.xml · nonDerivative · entry 1

Livingston Kevin Harold · CIK 0001828234 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 434,000

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on December 3, 2020. The original Form 4 had the incorrect transaction code.

F1 · price: Includes securities underlying the 24,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement upon the exercise in full of the over-allotment option granted to the underwriters to purchase additional shares in the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129500 · a4.xml · derivative · entry 2

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 136,667

Underlying: Class A Ordinary Shares · 136,667 shares

Expires not disclosed

F1 · security: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 136,667 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129500 · a4.xml · nonDerivative · entry 1

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 410,000

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129499 · a4.xml · derivative · entry 2

Consonance Life Sciences · CIK 0001824774 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,667

Underlying: Class A Ordinary Shares · 136,667 shares

Expires not disclosed

F1 · security: Includes securities underlying the 410,000 private placement units of the Issuer purchased by the Reporting Person for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 136,667 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by the Reporting Person for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.direct: The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129499 · a4.xml · nonDerivative · entry 1

Consonance Life Sciences · CIK 0001824774 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410,000

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by the Reporting Person for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.direct: The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129498 · a4.xml · derivative · entry 2

Livingston Kevin Harold · CIK 0001828234 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 136,667

Underlying: Class A Ordinary Shares · 136,667 shares

Expires not disclosed

F1 · security: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 136,667 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129498 · a4.xml · nonDerivative · entry 1

Livingston Kevin Harold · CIK 0001828234 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 410,000

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129496 · a4.xml · derivative · entry 2

Soffer Benny · CIK 0001829318 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 136,667

Underlying: Class A Ordinary Shares · 136,667 shares

Expires not disclosed

F1 · security: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F5 · security: Includes 136,667 warrants underlying the units referred to in footnote 1.

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001104659-20-129496 · a4.xml · nonDerivative · entry 1

Soffer Benny · CIK 0001829318 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 410,000

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion of the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-20-032813 · doc4.xml · nonDerivative · entry 3

BLUTT MITCHELL J MD · CIK 0001097955 · Director · 10% owner

Consonance Capital Management LP · CIK 0001544773 · Director · 10% owner

Consonance Capital Opportunity Fund Management LP · CIK 0001834998 · Director · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Managed Account

Disclosed balance after: 128,900

F1 · price: Represents part of units of Consonance-HFW Acquisition Corp. (the "Issuer") purchased in the Issuer's initial public offering for $10 per unit. Each unit consists of one Class A ordinary share ("Class A Share") of the Issuer and one-third of one warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants are not being reported on this Form 4 because they cannot be exercised until the satisfaction of material conditions outside the control of the Reporting Persons.

F6 · ownership.nature: Consonance Capital Opportunity Fund Management LP ("Consonance Opportunity") is an indirect beneficial owner of the Class A Shares held by a certain managed account (the "Managed Account"). Consonance Opportunity is the investment adviser of the Managed Account and exercises voting and investment power over the securities of the Issuer held by the Managed Account. Capman is the general partner of Consonance Opportunity. Consonance Opportunity receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman. Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of such securities of the Issuer except to the extent of their pecuniary interest therein.

SEC source: 0000899243-20-032813 · doc4.xml · nonDerivative · entry 2

BLUTT MITCHELL J MD · CIK 0001097955 · Director · 10% owner

Consonance Capital Management LP · CIK 0001544773 · Director · 10% owner

Consonance Capital Opportunity Fund Management LP · CIK 0001834998 · Director · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Capital Opportunity Master Fund, LP

Disclosed balance after: 371,100

F1 · price: Represents part of units of Consonance-HFW Acquisition Corp. (the "Issuer") purchased in the Issuer's initial public offering for $10 per unit. Each unit consists of one Class A ordinary share ("Class A Share") of the Issuer and one-third of one warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants are not being reported on this Form 4 because they cannot be exercised until the satisfaction of material conditions outside the control of the Reporting Persons.

F4 · ownership.nature: Consonance Management is an indirect beneficial owner of the Class A Shares held by Consonance Capital Opportunity Master Fund, LP ("Consonance Opportunity Master"). Consonance Management is the investment adviser of Consonance Opportunity Master, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by Consonance Opportunity Master. Capman is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the shares held by Consonance Opportunity Master as the manager and member of the general partner of Consonance Opportunity Master and thereby is entitled to a portion of the profits allocation.

F5 · ownership.nature: (Continued from footnote 4) Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of such securities of the Issuer except to the extent of their pecuniary interest therein.

SEC source: 0000899243-20-032813 · doc4.xml · nonDerivative · entry 1

BLUTT MITCHELL J MD · CIK 0001097955 · Director · 10% owner

Consonance Capital Management LP · CIK 0001544773 · Director · 10% owner

Consonance Capital Opportunity Fund Management LP · CIK 0001834998 · Director · 10% owner

Consonance Capman GP, LLC · CIK 0001620428 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Consonance Capital Master Account, LP

Disclosed balance after: 500,000

F1 · price: Represents part of units of Consonance-HFW Acquisition Corp. (the "Issuer") purchased in the Issuer's initial public offering for $10 per unit. Each unit consists of one Class A ordinary share ("Class A Share") of the Issuer and one-third of one warrant ("Warrant"), with each whole Warrant entitling the holder to purchase one Class A Share at $11.50 per share. The Warrants will not become exercisable until the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering. The Warrants are not being reported on this Form 4 because they cannot be exercised until the satisfaction of material conditions outside the control of the Reporting Persons.

F2 · ownership.nature: Consonance Capital Management LP ("Consonance Management") is an indirect beneficial owner of the Class A Shares held by Consonance Capital Master Account, LP (the "Master Account"). Consonance Management is the investment adviser of the Master Account, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by the Master Account. Consonance Capman GP LLC ("Capman") is the general partner of Consonance Management. Consonance Management receives an asset-based fee, but has no pecuniary interest. Mitchell Blutt is the manager and member of Capman and has a pecuniary interest in the shares held by the Master Account as the manager and member of the general partner of the Master Account and thereby is entitled to a portion of the profits allocation.

F3 · ownership.nature: (Continued from footnote 2) Each of Dr. Blutt, Consonance Management and Capman disclaims beneficial ownership of such securities of the Issuer except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-019995 · doc4a.xml · derivative · entry 8

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 136,667

Underlying: Class A Ordinary Shares · 136,667 shares

Expires not disclosed

F1 · security: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F5 · security: Includes 136,667 warrants underlying the units referred to in footnote 1.

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on November 25, 2020. The original Form 4 had the incorrect transaction code, and did not include reporting of all of the required transactions.

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F3 · derivative.exercise_date: The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: The warrants will expire five years after the completion of the Issuer's initial business combination.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-019995 · doc4a.xml · nonDerivative · entry 7

BLUTT MITCHELL J MD · CIK 0001097955 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 410,000

F6 · kind: This Form 4 amendment is being filed to correct the original Form 4 filed on November 25, 2020. The original Form 4 had the incorrect transaction code, and did not include reporting of all of the required transactions.

F1 · price: Includes securities underlying the 410,000 private placement units of the Issuer purchased by Consonance Life Sciences, LLC (the "Sponsor") for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.

F2 · ownership.nature: The Sponsor is the record holder of the shares and warrants reported herein. The Sponsor is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Sponsor and may be deemed to have shared beneficial ownership of the shares held by the Sponsor. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.